Entero Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
GridAI Technologies Corp. CEO Jason Sawyer reports vesting of 500,000 restricted stock units.
Director Jack Syage was granted 40,000 restricted stock units in GridAI Technologies Corp. which vested immediately on January 1, 2026.
GridAI Technologies Corp. Director Edward Borkowski was granted 40,000 restricted stock units, increasing his beneficial ownership to 60,248 shares.
GridAI Technologies Corp. Director Manpreet Uppal received a grant of 40,000 restricted stock units, which vested immediately.
GridAI Technologies Corp. Director Geordan Garrett Pursglove was granted 40,000 immediately vested restricted stock units.
GridAI Technologies Corp.'s CEO, Jason David Sawyer, was granted 40,000 restricted stock units that vested immediately on December 22, 2025.
GridAI Technologies Corp.'s Interim CFO, Anna Skowron, was granted 65,000 restricted stock units that vested immediately.
Sarah Romano, CFO of Entero Therapeutics, sold 727 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
Sarah Romano, CFO of Entero Therapeutics, sold 476 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
Sarah Romano, CFO of Entero Therapeutics, sold 621 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
Entero Therapeutics CEO James Sapirstein sold 1,289 shares of common stock on July 2, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Form 4: Chaitan Khosla, Entero Therapeutics Director, Acquires Shares Through Restricted Stock Units
Director Chaitan Khosla receives 24,889 restricted stock units in Entero Therapeutics, vesting in three equal installments.
James Sapirstein, CEO of First Wave BioPharma, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Sarah Romano, CFO of First Wave BioPharma, sold 75 shares of common stock on April 1, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
James Sapirstein, Chairman and CEO of First Wave BioPharma, sold 1,887 shares of common stock on March 15, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Sarah Romano, CFO of First Wave BioPharma, Inc., sold 1,120 shares of common stock on March 15, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Jack Syage, President and COO of First Wave BioPharma, acquired common stock and preferred stock through the company's merger with ImmunogenX.
Director Chaitan Khosla acquired common stock, preferred stock, and stock options in First Wave BioPharma through the company's merger with ImmunogenX.